Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Carcinoma 1

Interventions

Cyclophosphamide 47aldesleukin 30fludarabine phosphate 26fludarabine 24Carboplatin 18Rituximab 16Interleukin-2 16Cisplatin 16Bevacizumab 162,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 16Radiotherapy 15Paclitaxel 15Magnetic Resonance Spectroscopy 14Bortezomib 14Filgrastim 13Doxorubicin 13Oxaliplatin 12Erlotinib Hydrochloride 12Trastuzumab 11Leucovorin 11Etoposide 11Biopsy 11Taxes 10Radiation 10Fluorouracil 10alvocidib 9Specimen Handling 9Sorafenib 9Docetaxel 9Dexamethasone 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × NIH × Meperidine × Clear all
NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
36 enrolled 7 charts
Breast

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡